Orthometrix, Inc. Forms Alliance with Healthcare Reimbursement Solutions, Inc. to Provide Full Service to Podiatric and Orthope

ORTHOMETRIX, INC. (OTCBB: OMRX) today announced an
alliance with Healthcare Reimbursement Solutions, Inc. of Orlando,
Florida ("HRSI") to provide health care providers, such as those with
Podiatric and Orthopedic practices, using its new Orbasone(TM)
Extracorporeal Shock Wave Therapy ("ESWT") Pain Relief System with a
broad range of billing advisory services. The Orbasone(TM) ESWT Pain
Relief System received market approval from the U.S. Food and Drug
Administration in August 2005 for the treatment of chronic plantar
fasciitis (foot pain).
   The alliance allows purchasers of the Orbasone(TM) ESWT system to
avail themselves of HRSI's billing and reimbursement consulting
services HRSI's services range from updating known payer information
in a provider's geographical area, educational programs in the office
on the claim submission process, CPT code descriptions and the
preparation of medical necessity letters. In addition, a dedicated
reimbursement hotline will be available to Orbasone(TM) ESWT users for
one-on-one consulting and assistance with denial and claim review.
   Reynald Bonmati, Chairman and Chief Executive Officer of
Orthometrix, commented, "Access to reliable billing and reimbursement
information has become all the more valuable today to Podiatric and
Orthopedic practices as well as Pain Clinics providing ESWT procedures
since the new Category III Current Procedural Terminology (CPT) Code
28890 became effective as of January 1. Orthometrix is now providing
such service free of charge to purchasers of our Orbasone system."
   As a result of this alliance, the purchasers of the Orbasone(TM)
ESWT system will also have direct access to additional services
provided by HRSI. These include comprehensive turn-key billing and
reimbursement services and assistance in coordinating the use of the
Orbasone(TM) ESWT system amongst the providers to achieve maximum use
and benefit.
   Reynald Bonmati further stated, "Our intent is to make ESWT
treatment accessible to a larger segment of the U.S. population. This
alliance will make it easier for Podiatrists, Orthopedic Surgeons and
Pain Clinics to own an Orbasone and has already had a beneficial
impact on our sales." According to a survey conducted by the American
Podiatric Medical Association in 2000, 38.6 million Americans suffer
from plantar fasciitis. The condition particularly affects athletes
and the elderly.

   About Healthcare Reimbursement Solutions, Inc.

   Healthcare Reimbursement Solutions, Inc. has over ten years of
experience assisting various clients with the opportunity to sell,
perform and receive private payer reimbursement for new technology
procedures and treatments such as ESWT, without waiting for permanent
coding. These services allows providers the opportunity of an
immediate revenue pathway.

   About Orthometrix, Inc.

   Orthometrix, Inc. markets, sells and services several
musculoskeletal product lines used in pharmaceutical research,
diagnostic and monitoring of bone and muscle disorders, sports
medicine, rehabilitative medicine, physical therapy and pain
management.
   Our Web addresses are www.orthometrix.net, www.orbasone.com and
www.vibraflex.com.

   "Safe Harbor" Statement under the Private Securities Litigation
Reform Act of 1995: The statements which are not historical facts
contained in this release are forward looking statements that involve
risk and uncertainties, including, but not limited to, any effect on
future financial results from efforts to broaden the Company's
position in the rehabilitation, physical therapy and musculoskeletal
markets, any potential impact on sales of the Orbasone in North
America, and other risks detailed in the documents periodically filed
with the Securities and Exchange Commission, specifically the most
recent reports on Forms 10-KSB and 10-QSB. These risks and
uncertainties could cause actual results to differ materially from
those expected and/or contained in the forward-looking statements. Any
forward-looking statement made in this release is made as of the date
of this release and the Company assumes no obligation, subject to
applicable law, to update such forward-looking statement.